Astra rebuffs 'final' Pfizer bid

US drugs giant Pfizer's attempt to takeover AstraZeneca has come to a dead-end.

US pharmaceutical group Pfizer appears to have lost the battle for Anglo-Swedish rival AstraZeneca. The firm's final offer of £55 per share was rejected by Astra's board as inadequate.

Unless shareholders put pressure on the board to reconsider before the deadline of 26 May, Pfizer will have to wait three months to make a higher offer with Astra's approval, or six months if it wants to mount a hostile bid.

What the commentators said

A bid of £60 might well have tipped the balance, but by tabling a "take-it-or-leave-it" bid and urging Astra's shareholders to revolt, the firm badly miscalculated.

"Pfizer has a risky way back into a deal," said Chris Hughes on Breakingviews.com. It has the right to raise its final price if the offer is accepted, so it could signal to Astra's board that if Astra were to accept £55, Pfizer would immediately significantly increase it.

But the Takeover Panel, which oversees deals in the UK, would not be keen on an attempt to bend the rules and might well block the bid.

So could Pfizer return in six months? Probably not, said Kamal Ahmed on BBC.co.uk. By then, "AstraZeneca shareholders believe the US government will have gone a long way to closing the tax loophole which was one of the reasons for Pfizer being so attracted to AstraZeneca." The bid seems to be dead.

Recommended

The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Robin Geffen: dividend cuts aren't all down to Covid
Stockmarkets

Robin Geffen: dividend cuts aren't all down to Covid

The seeds of recent dividend cuts and cancellations were sowed many years ago, says veteran investor Robin Geffen.
25 Oct 2020
Dividend payments will take a long time to recover
Income investing

Dividend payments will take a long time to recover

Companies are gradually resuming dividend payouts, but we can expect only a modest rebound in 2021, says Cris Sholto Heaton.
25 Oct 2020
“Big Finance” comes out of its decade-long slump as bankers bounce back
Stockmarkets

“Big Finance” comes out of its decade-long slump as bankers bounce back

The financial sector was hammered by the crisis of 2008. Now, bankers are rediscovering their swagger, says Matthew Lynn.
25 Oct 2020

Most Popular

Negative interest rates and the end of free bank accounts
Bank accounts

Negative interest rates and the end of free bank accounts

Negative interest rates are likely to mean the introduction of fees for current accounts and other banking products. But that might make the UK bankin…
19 Oct 2020
Why commodities could be the best investment for 2021
Commodities

Why commodities could be the best investment for 2021

There’s plenty for investors to worry about right now. But things will inevitably recover. And the sector most likely to do best when they do, says Jo…
22 Oct 2020
UK post-Covid recovery stocks: these 20 companies could be set to rocket
Share tips

UK post-Covid recovery stocks: these 20 companies could be set to rocket

Finding stocks with the potential to rise tenfold or even further is far easier said than done. But the pandemic has produced the most promising backd…
22 Oct 2020